“Microdosing” means staying at, or below, the lowest labeled dose of semaglutide (0.25 mg a week) or tirzepatide (2.5 mg a week) instead of stepping up on the usual schedule. People ask about it for three reasons: fewer digestive side effects, lower cost, and the hope of keeping the benefits beyond weight loss with less medicine. It is a reasonable question. The honest answer is that the evidence is thin.
What has been studied
No randomized trial has been designed to test doses below the labeled starting dose of weekly semaglutide or tirzepatide for weight loss. The closest data come from an early dose-ranging study of daily semaglutide: over 52 weeks, adults with obesity lost about 6% of body weight on the smallest dose tested (0.05 mg a day) versus about 2% on placebo, and more at higher doses. That is a daily regimen, not the weekly one used today, so it only loosely applies.
A 2026 analysis of electronic health records from about 29 million patients looked at people who stayed on the lowest labeled doses for months. They lost modest weight, clearly less than people who escalated on schedule. The authors caution that people who do not escalate differ in many ways, and that prospective studies are needed before anyone can call microdosing effective.
What is marketed
Some clinics sell microdosing for longevity, inflammation or “metabolic balance.” None of those uses has been validated in a trial at low doses. The benefits beyond the scale described in our other article were measured at full doses, in people with specific conditions.
What is reasonable
- Starting low and stepping up slowly is standard practice, and it is how every labeled schedule begins.
- Holding a dose lower for longer is a legitimate medical decision when side effects, goals or weight already lost call for it.
- Staying low on purpose to “microdose for longevity” is, today, an experiment without a trial behind it.
How our physicians use dose
We prescribe on the labeled titration schedules and adjust them to you: slower when your stomach asks for it, held when you are at your goal, tapered when it is time. A lower dose that keeps you comfortable and progressing is good medicine. A lower dose sold as a longevity protocol is marketing.
If you are interested in a low-dose approach, say so in your consult. Your physician will tell you what it can and cannot do.
Explore weight loss treatmentsSources
- 1.O’Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018. The Lancet
- 2.Real-world outcomes of sustained low-dose semaglutide and tirzepatide exposure in 29 million patients (preprint, not yet peer-reviewed, 2026). Preprints.org
- 3.GLP-1 drugs have benefits beyond weight loss. Could microdoses preserve them? (review of the evidence, 2026). News-Medical